

#36/4  
(118)  
DmT  
4-23-02**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re Application of:  
Cottarel et al.

Serial No: 09/072,994

Filed: May 5, 1998

For: Cell-Cycle Regulatory Proteins  
from Human Pathogens, and Uses  
Related Thereto

Attorney Docket No. GPCI-P02-032

Art Unit: 1646

Examiner: M. Pak

GROUP 1600

APR 18 2002

FAX RECEIVED

**CERTIFICATE OF FACSIMILE**

I hereby certify that this correspondence is being transmitted by facsimile to the United States Patent and Trademark Office, Fax No. 703-308-4242, on the date indicated below:

April 17, 2002

Date of Signature  
and of Mail Deposit  
Brent LaBargeAssistant Commissioner of Patents  
Washington, D.C. 20231**REPLY UNDER 37 CFR 1.116**

Sir:

This amendment is being filed in reply to the outstanding Office Action, mailed May 9, 2001, and the Advisory Actions mailed December 17, 2001, and February 21, 2002, in connection with the above application. Please enter the following amendments:

**In the claims:**

For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below.

Please cancel claims 1-13, 15, 16, 23-36, and 39 without prejudice.

14. (Amended) A substantially pure nucleic acid comprising a nucleotide sequence which encodes a CAK1 polypeptide at least 75% identical to an amino acid sequence represented in SEQ ID No. 14, which CAK1 polypeptide binds a cyclin-dependent kinase and has a serine/threonine kinase activity.

OK TO E-TE 4/30/02 110

H1